Amarantus Bioscience Holdings Inc (AMBS)

[newflow]

Senate Votes 94 – 4 in Favor of 21st Century Cures Act #curesnow

Some of the highlights of the bill that are of interest to the rare disease community include:

$4.8 billion in new funding for the National Institutes of Health (NIH)
$500 million in new funding for the Food and Drug Administration (FDA)
Reauthorization of the Rare Pediatric Disease Priority Review Voucher program through 2020
Funding for the establishment of a national neurological disease surveillance system coordinated by the Centers for Disease Control and Prevention (CDC)
Improved biomarker qualification
Strengthened patient engagement at the FDA through the Patient Focused Impact Assessment Act
A regenerative medicine designation to allow such products to qualify for priority review and accelerated approval


One item that was dropped from the act was The Orphan Products Extensions Now, Accelerating Cures and Treatments (OPEN ACT) which would have provided an incentive for companies to repurpose existing drugs for rare disease indications.
http://www.raredr.com/news/senate-votes-94-4